tradingkey.logo

BUZZ-Hims & Hers shines bright in a testing year for telehealth stocks

ReutersDec 31, 2024 2:41 PM

Shares of Hims & Hers Health HIMS.N more than double, while other telehealth firms are set to end the year in declines

HIMS' shares set for their second straight year of gains helped by co's offering of compounded versions of GLP-1 weight-loss drugs such as Novo Nordisk's NOVOb.CO Wegovy

HIMS, Mangoceuticals MGRX.0, WeightWatchers WW.O and Teladoc Health TDOC.N offer compounded and branded versions of GLP-1 weight-loss drugs on their platforms

Soaring demand for weight-loss drugs made by Eli Lilly LLY.N and Novo Nordisk have pushed patients to cheaper compounded versions

Shares of telehealth firms have been volatile this year on "headlines tied to the overall supply availability of all things GLP-1-related," brokerage Leerink Partners says

Shares of TDOC and LFMD were also hit after Amazon AMZN.O announced low-cost telehealth services for Prime members; shares of LFMD fell to nearly four-month low

Shares of HIMS have more than doubled YTD

Shares of TDOC set for fourth straight year of decline, LFMD down 38.2% vs a ~327% gain in 2023; MGRX down 41% and WW down 85.5% vs a 126.7% gain in 2023

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI